1. Home
  2. NTLA vs PLYM Comparison

NTLA vs PLYM Comparison

Compare NTLA & PLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTLA
  • PLYM
  • Stock Information
  • Founded
  • NTLA 2014
  • PLYM 2011
  • Country
  • NTLA United States
  • PLYM United States
  • Employees
  • NTLA N/A
  • PLYM N/A
  • Industry
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • PLYM Real Estate Investment Trusts
  • Sector
  • NTLA Health Care
  • PLYM Real Estate
  • Exchange
  • NTLA Nasdaq
  • PLYM Nasdaq
  • Market Cap
  • NTLA 710.1M
  • PLYM 698.2M
  • IPO Year
  • NTLA 2016
  • PLYM 2017
  • Fundamental
  • Price
  • NTLA $8.12
  • PLYM $15.71
  • Analyst Decision
  • NTLA Buy
  • PLYM Buy
  • Analyst Count
  • NTLA 19
  • PLYM 9
  • Target Price
  • NTLA $38.26
  • PLYM $21.44
  • AVG Volume (30 Days)
  • NTLA 3.2M
  • PLYM 380.6K
  • Earning Date
  • NTLA 05-08-2025
  • PLYM 05-01-2025
  • Dividend Yield
  • NTLA N/A
  • PLYM 6.12%
  • EPS Growth
  • NTLA N/A
  • PLYM 600.05
  • EPS
  • NTLA N/A
  • PLYM 3.05
  • Revenue
  • NTLA $45,569,000.00
  • PLYM $180,505,000.00
  • Revenue This Year
  • NTLA N/A
  • PLYM $4.40
  • Revenue Next Year
  • NTLA N/A
  • PLYM $8.36
  • P/E Ratio
  • NTLA N/A
  • PLYM $5.15
  • Revenue Growth
  • NTLA N/A
  • PLYM N/A
  • 52 Week Low
  • NTLA $5.90
  • PLYM $12.70
  • 52 Week High
  • NTLA $28.18
  • PLYM $24.71
  • Technical
  • Relative Strength Index (RSI)
  • NTLA 50.39
  • PLYM 59.57
  • Support Level
  • NTLA $7.21
  • PLYM $15.05
  • Resistance Level
  • NTLA $9.27
  • PLYM $15.73
  • Average True Range (ATR)
  • NTLA 0.61
  • PLYM 0.40
  • MACD
  • NTLA 0.02
  • PLYM 0.19
  • Stochastic Oscillator
  • NTLA 44.20
  • PLYM 97.24

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About PLYM Plymouth Industrial REIT Inc.

Plymouth Industrial REIT Inc is a full-service, vertically integrated, self-administered, and self-managed Maryland corporation. It is focused on the acquisition, ownership, and management of single and multi-tenant Class B industrial properties, including distribution centers, warehouses, and light industrial properties, located in secondary and primary markets across the United States. The company has one reportable segment, which is Industrial properties. The majority of its property portfolio is spread across Florida, Ohio, Indiana, Tennessee, Illinois and Georgia, among others. It receives income from the rental revenue through its properties.

Share on Social Networks: